SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: margie who wrote (5463)10/6/1998 3:09:00 PM
From: Zirdu  Read Replies (1) of 6136
 
Margie, I don't see anything in the Rights agreement you quote that prevents the rights from being transferred along with the stock, when the stock is sold. Yes, the rights are given to all who are stockholders on a certain date. But the way it usually works, is that if and when those stockholders sell their stock, they are required to, and do, sell their "poison pill" rights along with their stock. So the new stockholder owns rights just like anyone else. If AGPH plan works differently than this, it would be unusual, in my experience.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News